Back to Search Start Over

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives.

Authors :
Roviello, Giandomenico
Catalano, Martina
Santi, Raffaella
Palmieri, Valeria Emma
Vannini, Gianmarco
Galli, Ilaria Camilla
Buttitta, Eleonora
Villari, Donata
Rossi, Virginia
Nesi, Gabriella
Source :
Cancers; Sep2021, Vol. 13 Issue 17, p4411, 1p
Publication Year :
2021

Abstract

Simple Summary: Urothelial bladder cancer (BC) is one of the most fatal cancers, with a dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant benefits of immunotherapy in advanced or metastatic bladder cancer have led to Food and Drug Administration (FDA) approval of immune checkpoint inhibitors (ICIs) as second- or first-line therapy in patients unresponsive to or ineligible for standard treatment. The advantage of ICIs is being investigated in various stages of BC, either as monotherapy or in combination with other drugs. In this review we discuss the role of ICIs in BC, highlighting their current clinical application and outlining future therapeutic perspectives. Bladder cancer (BC) is the most common malignancy of the genitourinary tract, with high morbidity and mortality rates. Until recently, the treatment of locally advanced or metastatic urothelial BC was based on the use of chemotherapy alone. Since 2016, five immune checkpoint inhibitors (ICIs) have been approved by the Food and Drug Administration (FDA) in different settings, i.e., first-line, maintenance and second-line treatment, while several trials are still ongoing in the perioperative context. Lately, pembrolizumab, a programmed death-1 (PD-1) inhibitor, has been approved for Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), using immunotherapy at an early stage of the disease. This review investigates the current state and future perspectives of immunotherapy in BC, focusing on the rationale and results of combining immunotherapy with other therapeutic strategies. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20726694
Volume :
13
Issue :
17
Database :
Complementary Index
Journal :
Cancers
Publication Type :
Academic Journal
Accession number :
152401772
Full Text :
https://doi.org/10.3390/cancers13174411